Piqray Európska únia - slovinčina - EMA (European Medicines Agency)

piqray

novartis europharm limited  - alpelisib - neoplazme dojke - antineoplastična sredstva - piqray je navedeno v kombinaciji z fulvestrant za zdravljenje pri ženskah po menopavzi, in moški, hormonski receptor (hr)-pozitiven, human epidermalna rast factor receptor 2 (her2)-negativna, lokalno napredno ali metastatskega raka dojke z pik3ca mutacije po napredovanja bolezni naslednje endokrine terapije kot monotherapy (glej poglavje 5.

Ayvakyt Európska únia - slovinčina - EMA (European Medicines Agency)

ayvakyt

blueprint medicines (netherlands) b.v. - avapritinib - gastrointestinalni stromalni tumorji - druga zdravila z delovanjem na novotvorbe agenti, protein kinaza inhibitorji - ayvakyt is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (gist) harbouring the platelet-derived growth factor receptor alpha (pdgfra) d842v mutation.

Medaxone 1 g prašek za raztopino za injiciranje/infundiranje Slovinsko - slovinčina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

medaxone 1 g prašek za raztopino za injiciranje/infundiranje

ceftriakson - prašek za raztopino za injiciranje/infundiranje - ceftriakson 1 g / 1 viala - ceftriakson

Medaxone 2 g prašek za raztopino za injiciranje/infundiranje Slovinsko - slovinčina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

medaxone 2 g prašek za raztopino za injiciranje/infundiranje

ceftriakson - prašek za raztopino za injiciranje/infundiranje - ceftriakson 2 g / 1 viala - ceftriakson

Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka) Európska únia - slovinčina - EMA (European Medicines Agency)

lenalidomide krka d.d. novo mesto (previously lenalidomide krka)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; lymphoma, follicular - imunosupresivi - multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) je indiciran za zdravljenje odraslih bolnikov s predhodno nezdravljenih več plazmocitom, ki niso primerni za presaditev. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) je indiciran za zdravljenje odraslih bolnikov s predhodno nezdravljenih več plazmocitom, ki niso primerni za presaditev. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Lenalidomide Krka d.d. Európska únia - slovinčina - EMA (European Medicines Agency)

lenalidomide krka d.d.

krka, d.d., novo mesto  - lenalidomide hydrochloride hydrate - multiple myeloma; lymphoma, follicular; myelodysplastic syndromes - imunosupresivi - multiple myelomalenalidomide krka d. as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) je indiciran za zdravljenje odraslih bolnikov s predhodno nezdravljenih več plazmocitom, ki niso primerni za presaditev. lenalidomide krka d. in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka d. as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. follicular lymphomalenalidomide krka d. in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).